VNS Therapy Receives FDA Approval for Expanded MRI Labeling
VNS Therapy remains the only device for epilepsy that is
“Our dedication to innovation has enabled
Currently, AspireHC® and AspireSR® models of VNS Therapy technology provide for this expanded MRI access, enabling patients to obtain high-quality MRI scans and optimize treatment. Additional benefits include:
• improving ease of use and access to care
• eliminating the need for special MRI equipment
• providing comprehensive treatment throughout a patient’s lifetime
“The FDA’s approval to expand our MRI labeling changes the landscape for
device-based epilepsy therapies,” adds
To date, VNS Therapy—a minimally invasive treatment designed to prevent seizures before they start and stop them if they do—has been used by more than 100,000 patients worldwide. More than one in three people with epilepsy has drug-resistant seizures, meaning seizures persist in spite of treatment with antiepileptic medications.1 It is estimated that approximately one million people suffer from drug-resistant epilepsy in the U.S. alone. To learn more, visit www.VNSTherapy.com or www.SeizureControl.com.
INTENDED USE/INDICATION
The VNS Therapy system is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications. Individual results may vary. Common side effects include hoarseness or changes in voice tone, prickling feeling in the skin, shortness of breath, sore throat and coughing. Visit www.VNSTherapy.com/important-safety-information to view safety and full prescribing information.
1. Kwan P.,
About
For more information, please visit www.livanova.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170621005163/en/
Source:
LivaNova PLC
Deanna Wilke, +1-281-727-2764
Corporate
External Communications Manager
corporate.communications@livanova.com
or
Havas
PR
Melissa Reiger, +1-412-251-2172
melissa.rieger@havas.com